Novo Nordisk and Maersk report profits of billions – but share values dip

Denmark’s largest company continues to grow significantly, but investors had expected even greater earnings from the slimming products Wegovy and Ozempic. The same applies to Maersk, which also makes a lot of money but not enough for the investors’ taste

Chief Executive Officer at Novo Nordisk Lars Fruergaard Jørgensen is happy with added growth and earnings. Photo: Novo Nordisk

Wednesday brought half-year accounts from two of Denmark’s most well-run and respected companies, Novo Nordisk and Maersk.For Novo Nordisk, operating profit grew by 18 percent compared to the first half of 2023. In the second quarter alone, sales have grown by 25 percent to DKK 68 billion.Ozempic and Wegovy drive growthThe sale of diabetes and […]


Gain unlimited access to all of The Copenhagen Post

Our independent reporting can only be published with support from our readers.

Monthly subscription

119

DKK/month.

(Billed once a month)

Give us a try

6 month subscription

99

DKK/month.

(Billed twice a year)

Save 120 DKK

Yearly subscription

79

DKK/month.

(Billed once a year)

Save 480 DKK

Save with a company subscription?




Connect Club is your gateway to a vibrant programme of events and an international community in Denmark.